Key Highlights
- ImmuPharma plc (LSE:IMM) traded below its 200-day moving average on Friday 16 October 2026, closing the week well short of its recent spike high.
- The AIM-listed shares had jumped more than 20 per cent on 9 October on heavy volume, without an accompanying company statement to explain the move.
- Management is targeting a value-enhancing commercial deal for its lead lupus candidate P140 during 2026, leaving roughly ten weeks to deliver on that goal.
- A £6.47 million fundraising completed in April is expected to fund operations into at least the second half of 2028, according to the directors.
- Interim results for the six months to 30 June 2026 showed a modest operating loss of £1.1 million, though a fair-value charge widened the headline loss.
Why ImmuPharma Is in Focus on 16 October 2026
ImmuPharma plc (LSE:IMM), the AIM-listed specialty biopharmaceutical group, was back on traders' screens on Friday 16 October 2026 after its shares moved beneath their 200-day simple moving average. Small-cap AIM biotechs often trade on sentiment and partnering expectations rather than revenue, and this stock carries a beta of about three. The stock touched an intraday low of about 3.60p and was last seen around 3.85p, compared with a 200-day average close to 4.07p and a 50-day average of roughly 3.63p. Around 2.1 million shares changed hands during the session, giving the company a market value in the region of £24 million.
The technical retreat comes only a week after a sharp rally. On Friday 9 October the shares climbed by about 21 per cent, moving from a previous close of 3.30p to trade near 4p after reaching an intraday high of 4.50p. Volume that day was approximately 7.8 million shares, more than three times the usual daily level. No regulatory announcement accompanied that surge, and Friday's slide back below the long-term trend line shows some of those gains being handed back while the market waits for concrete news.
The P140 Story Behind the Volatility
The investment case for LSE:IMM remains centred on P140, a peptide previously developed under the Lupuzor name. The company describes it as a first-in-class autophagy immunomodulator for systemic lupus erythematosus, a chronic autoimmune disease with significant unmet medical need. Preclinical work has also suggested potential activity in other autoimmune conditions that share the same underlying mechanism.
In September 2026 the company filed an international patent application under the Patent Cooperation Treaty covering a precision medicine approach to P140. That filing protects work on a biologically defined patient group, labelled Type M, whose immune profile is associated with a stronger likelihood or magnitude of response to the drug. The application built on a UK priority filing from August 2025 and incorporated fresh experimental data generated over the following twelve months.
Partnering is the near-term value lever. ImmuPharma has described its discussions with US licensing partner Avion Pharmaceuticals as constructive and has repeatedly said it aims to secure a value-enhancing commercial deal for P140 during 2026. No such agreement had been announced by mid-October, which explains why any rumour or volume spike in ImmuPharma plc (LSE:IMM) tends to produce exaggerated price swings.
Kapiglucagon Adds a Second Leg
Beyond P140, the company is advancing Kapiglucagon, a glucagon programme that became a priority following this year's fundraising. During the first half, ImmuPharma finalised its overall development plan across regulatory, manufacturing, nonclinical and bioanalytical workstreams, selected specialist development partners, and progressed preparations for interaction with the US Food and Drug Administration to shape the investigational new drug enabling programme.
Financial Position and Funding Runway
The interim results published on 15 September 2026 showed an operating loss of £1.1 million for the six months to 30 June, slightly narrower than the £1.2 million recorded a year earlier. Research and development spending was about £0.6 million and administrative costs about £0.4 million. The headline loss rose to £4.7 million, largely because of a non-cash finance loss of around £3.4 million from revaluing a derivative financial asset linked to the share price. Cash at the period end stood at £0.7 million, with the derivative asset valued at about £2 million.
That derivative stems from the funding structure. In April 2026, after shareholder approval at a general meeting, ImmuPharma completed a £6.0 million subscription with long-standing investor Lanstead Capital Investors alongside a retail offer of roughly £0.47 million, for gross proceeds of about £6.47 million. The Lanstead money is subject to a 20-month sharing agreement, so the cash ultimately received depends on the share price relative to a benchmark. The directors have said that the new funds, together with existing resources, should provide a runway to at least the second half of 2028.
Risks Investors Should Weigh
The key risk for ImmuPharma plc (LSE:IMM) is partnering execution: if a P140 transaction does not materialise in 2026 as guided, sentiment could deteriorate quickly. A falling share price could also reduce the cash received under the sharing agreement. The company remains loss-making, and its assets carry development and regulatory risk.
What Investors Are Watching Next
Over the coming weeks, shareholders will look for any update on the P140 commercial deal, progress on the international patent process, and further detail on the Kapiglucagon regulatory pathway. Investors following LSE:IMM will also watch whether the shares can reclaim the 200-day moving average.






Please wait processing your request...